Small bowel thickening at imaging as predictor of clinical response to teduglutide, a glucagon-like peptide-2 (glp-2) analog, in patients with short bowel syndrome with chronic intestinal failure

Abstract

Listen

Translate article

Rationale: Short bowel syndrome with chronic intestinal failure (SBS – CIF) is a condition that results from surgical resection or congenital disease of the small intestine which is characterized by the inability to maintain protein-energy, fluid, electrolyte, or micronutrient balances and required parenteral support. Teduglutide (TED) is a Glucagon-like peptide-2 analog and results with improvements in the absorption of macronutrients and electrolytes and decrease on parenteral support dependency.